John Delehanty

2.0k citations

13 papers · 1.5k indexed · 1 hit paper · h-index 11

Co-authors: Ralph DeMasi Miklos Salgo Jacob Lalezari Sharon Walmsley Keith Henry Joseph J. Eron Peter J. Piliero Benoît Trottier
Topics: HIV Research and Treatment (6 papers)HIV/AIDS drug development and treatment (6 papers)HIV/AIDS Research and Interventions (4 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: New England Journal of Medicine The Journal of Infectious Diseases Antimicrobial Agents and Chemotherapy
Partner nations: United States Spain Italy

In The Last Decade

John Delehanty

12 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Keith Henry et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by John Delehanty

Since Specialization

Citations

This map shows the geographic impact of John Delehanty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Delehanty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Delehanty more than expected).

Fields of papers citing papers by John Delehanty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Delehanty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Delehanty. The network helps show where John Delehanty may publish in the future.

Co-authorship network of co-authors of John Delehanty

This figure shows the co-authorship network connecting the top 25 collaborators of John Delehanty. A scholar is included among the top collaborators of John Delehanty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Delehanty. John Delehanty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America 2020 ·UNC Libraries ·Mary O’Hearn,Jain Chung,Peter J. Piliero,Benoît Trottier,Keith Henry,Calvin Cohen,Ralph DeMasi,Miklos Salgo,(unknown),(unknown),Joan Montaner,Sharon Walmsley,Daniel R. Kuritzkes,John Delehanty,Joseph J. Eron,Jacob Lalezari	0
2	Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients 2003 ·Journal of Clinical Virology ·David A. Wheeler,Jacob Lalezari,J Michael Kilby,Joseph Wheat,John Delehanty,Ralph DeMasi,Indravadan H. Patel,Miklos Salgo	18
3	Enfuvirtide (T‐20) Cross‐Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide 2003 ·The Journal of Infectious Diseases ·Sharon Walmsley,Keith Henry,Christine Katlama,Mark Nelson,Antonella Castagna,Jacques Reynes,Bonaventura Clotet,James Hoi Po Hui,Miklos Salgo,Ralph DeMasi,John Delehanty	29
4	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South Americabreakdown → 2003 ·New England Journal of Medicine ·Jacob Lalezari,Keith Henry,Mary O’Hearn,Joan Montaner,Peter J. Piliero,Benoît Trottier,Sharon Walmsley,Calvin Cohen,Daniel R. Kuritzkes,Joseph J. Eron,Jain Chung,Ralph DeMasi,(unknown),(unknown),John Delehanty,Miklos Salgo	716
5	Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia 2003 ·New England Journal of Medicine ·Adriano Lazzarin,Bonaventura Clotet,David A. Cooper,Jacques Reynes,Keikawus Arastéh,Mark Nelson,Christine Katlama,Hans-Jürgen Stellbrink,Jean-François Delfraissy,Joep M. A. Lange,Les Huson,Ralph DeMasi,Cynthia Wat,John Delehanty,(unknown),Miklos Salgo	493
6	A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults 2003 ·Antiviral Therapy ·Jacob Lalezari,Edwin DeJesus,Donald W. Northfelt,Gary Richmond,Peter Wolfe,Richard Haubrich,David Henry,William G. Powderly,Stephen Becker,Melanie Thompson,Fred Valentine,David P. Wright,Margrit Carlson,Sharon A. Riddler,(unknown),Ralph DeMasi,Prakash Sista,Miklos Salgo,John Delehanty	61
7	Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus Infection 2002 ·Antimicrobial Agents and Chemotherapy ·Robert G. Gish,Nancy W.Y. Leung,Teresa L. Wright,Huy N. Trinh,William Lang,Harold A. Kessler,(unknown),(unknown),John Delehanty,(unknown),Elsa Mondou,A. Lynn Snow,Franck Rousseau	68
8	Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection 1993 ·Journal of Medical Virology ·Sharon Safrin,Timothy W. Schacker,John Delehanty,Edgar L. Hill,Lawrence Corey	10
9	Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir 1993 ·Antimicrobial Agents and Chemotherapy ·Sharon Safrin,Timothy W. Schacker,John Delehanty,Edgar L. Hill,Lawrence Corey	16
10	Effect of topical carteolol on the normal human retinal circulation. 1992 ·PubMed ·J E Grunwald,John Delehanty	31
11	A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma 1991 ·Graefe s Archive for Clinical and Experimental Ophthalmology ·(unknown),M. Bruce Shields,Robert C. Allen,Richard A. Lewis,John Cohen,H. Dunbar Hoskins,(unknown),(unknown),(unknown),John Delehanty	23
12	Approaches to determining mutation rates in human DNA 1986 ·Mutation Research/Reviews in Genetic Toxicology ·John Delehanty,R. White,Mortimer L. Mendelsohn	30
13	The use of recombinant DNA technology to study gene alteration 1985 ·Mutation Research/Reviews in Genetic Toxicology ·(unknown),John Delehanty,P.H.M. Lohman,J. Brouwer,P. van de Putte,P. Pearson,Peter H. Pouwels,Claes Ramel	7

About John Delehanty

John Delehanty is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 13 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV Research and Treatment (6 papers), HIV/AIDS drug development and treatment (6 papers) and HIV/AIDS Research and Interventions (4 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.2k citations) and Hepatology (155 citations). John Delehanty has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Ralph DeMasi, Miklos Salgo, Jacob Lalezari, Sharon Walmsley, Keith Henry, Joseph J. Eron, Peter J. Piliero, Benoît Trottier, Daniel R. Kuritzkes and Joan Montaner. Their work appears in journals such as New England Journal of Medicine, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact